A Bitter Brew For Cancer: EGCG’s Impact on Ewing Sarcoma Cells

Authors

Lizzeth Holguin, St Mary's UniversityFollow
Mary-Esther Leblanc, St Mary's UniversityFollow
Mariana Reyes, St Mary's UniversityFollow
Terry Jo Shackleford, St Marys UniversityFollow

Files

Publication Date

Spring 5-15-2025

Keywords

Cancer, Ewing Sarcoma, EGCG, Epigallocatechin Gallate, Green Tea, Incucyte, Cancer Therapeutics, Pediatric Cancer

Description

Epigallocatechin Gallate (EGCG), a powerful antioxidant found in green tea, is an abundant treatment to treat Ewing Sarcoma cells, a pediatric cancer affecting the skeletal system. Given EGCG’s known role in other cancer treatments, these tests aim to investigate its effects as a standalone natural compound on Ewing Sarcoma cells. Focusing on the PI3K/AKT pathway, if the PI3K/AKT pathway is inhibited by EGCG, then it will lead to reduced cell survival and proliferation of EW8 cells. Using cell culture techniques, IncuCyte-based IC50 analysis, caspase 3/7, RNA purification, cDNA synthesis, and qRT-PCR, EGCG’s impact was assessed on cell apoptosis and gene expression. Results showed that EGCG did affect Ewing sarcoma cells by inducing apoptosis in a dose-dependent manner, though its effects were less potent than hypothesized. These findings suggest that while EGCG exhibits anticancer properties, it may be more effective in a synergistic manner rather than as a standalone therapy.

Format

pdf

Medium

Lab report, poster

Size or Duration

12

City

San Antonio

Recommended Citation

Holguin, Lizzeth; Leblanc, Mary-Esther; Reyes, Mariana; and Shackleford, Terry Jo, "A Bitter Brew For Cancer: EGCG’s Impact on Ewing Sarcoma Cells" (2025). Cell and Molecular Methods. 7.
https://commons.stmarytx.edu/biostulab25/7